Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Buying Veracyte Inc (VCYT)

Page 1 of 2

Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index returned about 5.2% during the last 12 months ending October 30, 2015. Less than 49% of the stocks in the index outperformed the index. This means you (or a monkey throwing a dart) have less than an even chance of beating the market by randomly picking a stock. On the other hand, the top 30 S&P 500 stocks among hedge funds at the end of September 2014 had an average return of 9.5% during the same period. Sixty three percent of these 30 stocks outperformed the market. Hedge funds had bad stock picks like everyone else. Micron, which lost 50% over this period, was one of hedge funds’ 30 favorite S&P 500 stocks. Anadarko Petroleum was another failed stock pick which lost more than 26%. So, taking cues from hedge funds isn’t a foolproof strategy, but it seems to work on average. In this article, we will take a look at what hedge funds think about Veracyte Inc (NASDAQ:VCYT).

Veracyte’s stock has jumped by more than 10% in the last month, but it is still 29% in the red year-to-date. Nevertheless, during the third quarter the number of funds bullish on the stock, among those that we track, inched up and we have decided to take a look at which funds are betting on the biotech company. At the end of this article we will also compare VCYT to other stocks, including Cadiz Inc (NASDAQ:CDZI), Layne Christensen Company (NASDAQ:LAYN), and BioScrip Inc. (NASDAQ:BIOS) to get a better sense of its popularity.

Follow Veracyte Inc. (NASDAQ:VCYT)
Trade (NASDAQ:VCYT) Now!

To the average investor there are plenty of gauges stock traders put to use to value stocks. A pair of the most useful gauges are hedge fund and insider trading interest. Our experts have shown that, historically, those who follow the top picks of the elite fund managers can outpace the broader indices by a very impressive amount (see the details here).

With all of this in mind, let’s take a gander at the fresh action surrounding Veracyte Inc (NASDAQ:VCYT).

How have hedgies been trading Veracyte Inc (NASDAQ:VCYT)?

At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey were bullish on this stock, up by one over the quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were upping their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Charles Clough’s Clough Capital Partners has the most valuable position in Veracyte Inc (NASDAQ:VCYT), worth close to $6.6 million, accounting for 0.3% of its total 13F portfolio. On Clough Capital Partners’s heels is Stephen DuBois’ Camber Capital Management, with a $4.3 million position; 0.4% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors with similar optimism encompass Behzad Aghazadeh’s venBio Select Advisor, Kevin Kotler’s Broadfin Capital, and Israel Englander’s Millennium Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!